FeedbackModule 4: treatment and care
Image
Treatment
Annex 6. Statistical analysis plans
WHO treatment guidelines for drug-resistant TB treatment
WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update
Refer to Annex 10: Summaries of unpublished data and analysis plans used for the recommendations in the WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update.
https://iris.who.int/bitstream/handle/10665/311390/WHO-CDS-TB-2019.3-eng.pdf
3.2 Drug-resistant tuberculosis treatment
WHO guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update
Funding for the meetings and reviews involved in the updating of the guidelines came entirely from the United States Agency for International Development (USAID). The experts on the Guideline Development Group (GDG) and the institutions where they work contributed time for the various discussions and other activities involved in the update process.
3.1 Drug-susceptible tuberculosis treatment
2009 Guideline Development Group:
All members of the group completed a Declaration for the Conflict of Interest; there were no conflicts declared.
2016 Guideline Development Group:
The following members declared no interests: Si Thu Aung; Frank Bonsu; Jeremiah Chakaya; Lucy Chesire; Daniela Cirillo; Poonam Dhavan; Kathy Fiekert; Andrei Mariandyshev; Nguyen Viet Nhung; Ejaz Qadeer; Abdul Hamid Salim; Holger Schünemann; Pedro Suarez; Justin Wong Yun Yaw.
2.2 Expert panels
Drug-susceptible TB treatment
Participants in the Guideline Development group meeting on Drug-susceptible TB in 2009
Guideline Development Group
Solange Cavalcante, TB Control Program Coordinator, Rio de Janeiro municipality, Rio de Janeiro, RJ, Brazil
Jeremiah Muhwa Chakaya (Chairperson), Technical Expert, National Leprosy and TB Programme, Kenya Medical Research Institute, Nairobi, Kenya